The Other Arms Race argued that U.S. gray-market peptides and China-to-West licensing are not separate accidents—they reflect divergent regulatory optimization on shared manufacturing muscle. Here is what that implies if you are watching listed equities and policy calendars.
What the thesis suggests watching
Irreversibility is the market mechanism. Western majors built China strategies around west-to-east licensing; reversing that flow leaves footprints—Drug Master Files, approved plants, partnership economics—that do not unwind cleanly when headlines change.
Signal 1 — Novo Nordisk in Greater China. Competitive substitution shows up first where domestic innovators have regulatory parity. Media outlets cited Novo reporting semaglutide-related pressure in China around mid-2025—including wholesaler timing effects—and Reuters tracked management commentary as competitive dynamics intensified into late 2025. Treat headline percentages carefully—inventory noise versus share shift—but treat China revenue disclosure as a primary dial.
Signal 2 — Chinese outbound licensing velocity. Chinese drugmakers recorded roughly $136 billion in out-licensing deals in 2025—more than double 2024’s pace—per Hong Kong tabulations widely summarized in the trade press. If that deal velocity stays elevated while FDA pathways remain navigable, Western majors are not dabbling; they are systematically outsourcing pipeline risk westward.
Signal 3 — Lilly versus Innovent in obesity. Lilly retains global rights outside China for mazdutide while Innovent holds China rights under their legacy agreement (Innovent approval announcement). Lilly’s commentary on China pricing and share—and any strategic adjustments—in quarterly calls is the cleanest read-through on whether dual-channel competition is margin noise or structural.
The bull case
If the dual-channel thesis holds, Novo remains the cleanest Western casualty on China substitution timelines—not because it is poorly run, but because its franchise skew exposes early revenue pressure while competitors diversify. The outbound-licensing wave simultaneously validates Chinese innovators as capital-efficient pipeline factories for Western balance sheets hunting patent-cliff fill-ins (deal-volume reporting). GSK’s large Hengrui alliance exemplifies the basket structure majors now use to acquire optionality.
Asymmetry: Novo already trades with obesity uncertainty discounted; if China deterioration undershoots priced decline paths, the squeeze thesis slows—but if FY 2026 guidance proves optimistic on China substitution, downside gap risk remains.
The bear case
FDA peptide compounding pathway. If HHS/FDA restores compounded supply channels that pull patients back under domestic pharmacy oversight, gray-market demand elasticity shifts—and part of the political pressure story relaxes for incumbents.
FDA evidence standards. If U.S. regulators require expansive replication—not bridging—for China-first metabolic drugs, licensing economics lengthen and milestones defer; Sciwind-family FDA timelines become the precedent watch.
Best-in-class versus first-in-class. Much outbound licensing optimizes known mechanisms; foundational IP for the next target class can still live elsewhere. Phase 3 Western readouts for genuinely novel Chinese biology—not incremental GLP-1 derivatives—are the ceiling tests.
The tracked call
Tracked call: Novo Nordisk’s Greater China GLP-1–oriented franchise revenue falls ≥15% year-over-year at constant exchange rates for FY 2026 versus FY 2025, as domestic innovators accelerate share capture.
Falsification window: Novo Nordisk FY 2026 annual filing—typically February–March 2027.
Confidence: Medium.
What would change my mind
-
FDA materially reopens compounded peptide supply in 2026–2027 such that gray-market economics weaken—relief for pricing power at Novo/Lilly on the margin.
-
Novo announces structural collaboration with a Chinese GLP-1 developer (license, co-development, or acquisition) aimed at neutralizing domestic substitution—a signal competition is being arbitraged rather than absorbed as revenue loss.
-
FY 2026 Greater China reporting stabilizes GLP-1–linked revenue versus FY 2025 at CER despite competitor approvals—undercutting the compression mechanism.
Related: The Other Arms Race — the core essay’s evidence and falsifiers.
This companion is not investment advice. Working Hypothesis publishes tracked calls for accountability; markets can remain irrational versus fundamentals longer than forecasts anticipate.
If you found this useful, the best thing you can do is forward it to one person who would push back on it. I’d rather be wrong in public than right in private.